AUS
NZ
UK
CA
USA
IND
Highlights
- Clinical Progress: First subject dosed in a Phase 1b study evaluating TRP-8803 in obese participants.
- Study Goals: Aims to assess pharmacokinetic differences compared to non-obese patients.
- Advancing to Phase 2: Data will optimize dosing for future clinical trials in targeted indications.
Tryptamine Therapeutics Limited (ASX:TYP), a clinical-stage biopharmaceutical company, announced the successful and safe dosing of the first participant in its Phase 1b obesity-focused study for TRP-8803. This proprietary, IV-infused psilocin formulation is designed to leverage neuroplastic benefits for innovative therapeutic applications.
Study Design and Objectives
The ongoing open-label study, conducted at CMAX Clinical Research in Adelaide, aims to investigate pharmacokinetic differences in TRP-8803's effects between obese and non-obese subjects. The study builds upon the existing Phase 1b protocol, with the inclusion of three obese participants to generate insights specific to this population.
The first subject received a 140-minute IV infusion of TRP-8803 on 21 November 2024 and safely completed follow-up assessments before being discharged. The remaining two participants are scheduled for dosing in the coming weeks.
The data collected from this study will inform dosing strategies for the company’s upcoming Phase 2 clinical program, targeting specific therapeutic indications. Interim results are expected later this year, providing valuable insights into dose optimization for obese populations.
TRP-8803: A Transformative Psilocin-Based Formulation
TRP-8803 is Tryptamine Therapeutics' flagship asset. Unlike traditional oral psilocybin treatments, this innovative IV formulation:
- Accelerates onset of the neuroplastic state.
- Provides better control over the depth and duration of the experience.
- Reduces intervention time to a commercially viable framework.
These features address key limitations of oral psilocybin, making TRP-8803 a promising candidate for various unmet medical needs.
Previous Success in Binge Eating Disorder
The company has already demonstrated the potential of TRP-8803 through a Phase 2a trial at the University of Florida. In this study, patients with binge eating disorder achieved an 80% reduction in binge episodes, underscoring the formulation's therapeutic efficacy and commercial promise.
Looking Ahead
Tryptamine Therapeutics continues to advance its clinical pipeline with a focus on TRP-8803. This study in obese participants represents a significant step in optimizing the treatment for broader populations and preparing for Phase 2 trials.
As interim results are anticipated by year-end, stakeholders remain optimistic about the potential for TRP-8803 to address critical therapeutic gaps while reinforcing Tryptamine Therapeutics’ position as an innovator in the biopharmaceutical space.
